William R Friedenberg
Overview
Explore the profile of William R Friedenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
111
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kyle R, Jacobus S, Friedenberg W, Slabber C, Rajkumar S, Greipp P
Cancer
. 2009 Feb;
115(10):2155-64.
PMID: 19248045
Background: A randomized controlled trial tested the hypothesis that aggressive initial therapy using high-dose cyclophosphamide (HiCy) and alpha(2)beta interferon (IFN) may be superior to standard combination alkylating agent regimens in...
2.
Friedenberg W, Rue M, Blood E, Dalton W, Shustik C, Larson R, et al.
Cancer
. 2006 Jan;
106(4):830-8.
PMID: 16419071
Background: Preliminary studies have shown valspodar (PSC-833: Novartis Pharmaceuticals, East Hanover, NJ) to be a potent inhibitor of multidrug resistance (MDR), one cause of resistance to chemotherapy. An international randomized...
3.
Witzig T, Vukov A, Habermann T, Geyer S, Kurtin P, Friedenberg W, et al.
J Clin Oncol
. 2005 Jan;
23(6):1103-8.
PMID: 15657404
Purpose: Patients with newly diagnosed, advanced-stage, follicular grade 1 non-Hodgkin's lymphoma (NHL) are often asymptomatic and can be observed without immediate chemotherapy. The goals of this study were to assess...
4.
Friedenberg W, Tallman M, Brodsky I, Paietta E, Rowe J, Lee S, et al.
Leuk Res
. 2004 Jun;
28(8):813-9.
PMID: 15203279
Background & Method: The role of multidrug resistance (MDR) was investigated in patients with relapsed chronic lymphocytic leukemia (CLL). PSC-833 was added to modified VAD (a 4-day infusion of vincristine,...
5.
Friedenberg W, Graham D, Greipp P, Blood E, Winston R
Leuk Res
. 2003 Jun;
27(8):751-4.
PMID: 12801534
Background: Docetaxel has activity against multiple malignancies. In a previous ECOG study of untreated patients with multiple myeloma, paclitaxel was found to have mild activity, but had excessive toxicity. Docetaxel...